Kornimate/medical-research-clean huggingface dataset:
autologous lung stem cell transplantation in patients with interstitial lung diseases

Conditions: Interstitial Lung Diseases

Summary: interstitial lung diseases (ild) are a group of diseases affecting the lung interstitium. the lung scarring that occurs in ild is often irreversible with only mitigating therapy available so far. this study intends to carry out an open, single-armed, phase i/ii clinical trial to investigate whether lung stem cells can regenerate damaged lung tissue. during the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. after careful characterization, cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy. the safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.


Eligibility criteria:
inclusion criteria: * diagnosed with interstitial lung disease * clinically stable * written informed consent signed exclusion criteria: * allergic to cell therapy; * patients with serious significant pulmonary infection need anti-infection treatment; * patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3 months; * patients with malignant tumor in the past 5 years; * participated in other clinical trials in the past 3 months; * patients with serious heart disease(nyha class ⅲ-ⅳ) * pregnant or lactating women; * the investigator assessed as inappropriate to participate in this clinical trial.
spi-directed analgesia for vitreoretinal surgeries

Conditions: Vitreoretinal Surgeries; Postoperative Nausea and Vomiting; Postoperative Pain

Summary: the aim of this randomized trial is to assess the efficacy of spi-directed analgesia for vitreoretinal surgeries (vrs), presence of ponv and oculocardiac reflex (ocr) and compare numerical rating scale (nrs) with surgical pleth index (spi) for monitoring pain perception postoperatively. patients received general anaesthesia alone or combined with either preemptive analgesia using topical solution of 0,5% proxymetacaine or peribulbar block (0,5% bupivacaine with 2% lidokaine) or preemptive intravenous infusion of 1,0 g of metamizol or preemptive intravenous infusion of acetaminophen in a doseof 10-15mg/kg of body weight.

monitoring depth of anaesthesia using spectral entropy (se) and quality of neuromuscular block are routine in modern anaesthesia, whereas monitoring of analgesia still requires further studies. recently, the surgical pleth index (spi) was added as a surrogate variable showing the nociception-antinociception balance into abovementioned parametres constituting a novel approach in monitoring patients intraoperatively, known as adequacy of anaesthesia (aoa) or tailor-made anaesthesia.

Eligibility criteria:
inclusion criteria: * written consent to participate in the study * written consent to undergo general anaesthesia alone or combined with different techniques of pre-emptive analgesia and vitreoretinal surgery exclusion criteria * history of allergy to local anaesthetics or metamizole * necessity of administration of vasoactive drugs influencing spi monitoring * pregnancy

Keywords: surgical pleth index (spi) general anaesthesia (ga), numerical rating scale (nrs) adequacy of anaesthesia (aoa) peribulbar block (pbb) topical analgesia (ta) oculocardiac reflex (ocr) postoperative nausea nad vomiting (ponv) paracetamol metamizol
effectiveness of different candies against bad breath

Conditions: Bad Breath

Summary: this study is to analyze whether the candies can relieve or eliminate bad breath, both subjectively and objectively.

this study is to systematically examine an existing candy, which is easily available and is intended to relieve or eliminate bad breath. the main aim of the study is to determine the effectiveness of the candies on the subjective perception of bad breath. the secondary outcome of the study is to investigate whether there is actually a decrease in volatile sulphur compounds (vsc) in the exhaled air and also a decrease in bad breath during organoleptic measurement. the purpose of the study is to investigate whether the different candies can relieve or eliminate bad breath, both subjectively and objectively.

Eligibility criteria:
inclusion criteria: * non- smoker * no general medical illness or medication exclusion criteria: * allergies/intolerances to ingredients of the products used * chronic diseases * smoker * pregnancy

Keywords: halitosis volatile sulphur compounds
alzheimer and music therapy: effects of music lessons on brain plasticity, mood, and quality of life in alzheimer patients

Conditions: Alzheimer Disease; Mild Cognitive Impairment; MCI With Increased Risk for Alzheimer Disease

Summary: music has powerful effects on memory in patients with neurodegenerative diseases. however, although there is anecdotal evidence for beneficial effects of active music interventions in patients with alzheimer's disease (ad), there is lack of high-quality research investigating this issue, and the cognitive, emotional, and social factors that contribute to potentially beneficial effects of music making in ad patients are largely unknown. in a randomised controlled intervention trial, a cohort of ad patients will undergo twelve months of music lessons specifically tailored for ad patients. structural and functional magnetic resonance imaging (mri) will be used to determine changes in brain age (as compared to two control groups), and voxel-based morphometry will be computed to determine contributions of different factors of the music intervention (cognitive, emotional, and social) to plastic changes of brain morphology, and a potential deceleration of brain atrophy. in addition, quality of life of patients. in cooperation with the bergen municipality, and a strong network of national and international partners, the neurocognitive music therapy will be implemented, involving training of music therapists, and communication of results to patients, patient groups, and therapists.


Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer disease * living independently at home (not in a care home or similar aged care facility) * able to complete questionnaires in norwegian * able to undergo mri scans * able to attend interventions and assessments in the area of bergen, norway * has given informed consent exclusion criteria: * hearing impairment that cannot be mended by hearing aids * conditions that hinder mri scans, such as claustrophobia or metal objects in body (e.g. pacemakers)
"real-life" cohort of patients with chronic hepatitis b virus infection

Conditions: Hepatitis B

Summary: it is estimated that 350-400 million people worldwide are chronically infected with hepatitis b virus (hbv). cirrhosis and hepatocellular carcinoma are major complications of chronic hbv infection and are responsible of about 500,000 deaths each year. although some predictive factors of the outcome of chronic hbv infection were reported, it remains needed to more precisely determine the factors which are associated with the outcome in non-selected patients. indeed, these factors should help to identify patients who are likely to have a better or worse evolution of their chronic hbv infection over time and thus, to adapt their clinical management and monitoring.therefore, our purpose is to constitute a "real-life" cohort of non-selected patients to create a database of epidemiological, clinical, biological, virological and therapeutic parameters, in order to determine factors associated with the outcome of chronic hbv infection.


Eligibility criteria:
inclusion criteria: * patients with chronic hbv infection (defined as hbsag positive for at least 6 months) exclusion criteria: * co-infection with human immunodeficiency virus (hiv), hepatitis c virus (hcv) and/or hepatitis d virus (hdv) * decompensated cirrhosis * history of liver transplantation * history of hepatocellular carcinoma (hcc)

Keywords: hepatitis b
device-guided breathing for shortness of breath in copd

Conditions: COPD; Dyspnea; Hyperinflation

Summary: although drug therapies and pulmonary rehabilitation have greatly improved copd symptoms, as many as 50% of patients with severe copd have inadequately controlled dyspnea. device-guided breathing is a behavioral intervention that guides respiratory rates into a therapeutic range; prolongation of the expiratory phase improves hyperinflation, the most significant driver of dyspnea in this population. device-guided breathing, has no known side-effects, and may represent a cost effective adjunctive treatment for dyspnea in severe copd.


Eligibility criteria:
inclusion criteria: * current or former cigarette smokers of at least 10 pack-years * clinically significant dyspnea, as determined by a score of at least 2 on the medical research council dyspnea score questionnaire (0-4), or through pulmonary function test results of a residual volume (rv) of \> 150% predicted or an fev1 of \<65% predicted * clinical diagnosis of chronic obstructive pulmonary disease exclusion criteria: * unable to use the slow-breathing device due to hearing impairment * poor motivation or lack of interest in using the device * pulmonary rehabilitation ordered as a new therapy at the time of enrollment

Keywords: copd biofeedback dyspnea quality of life stress
end-of-life communication from a chinese perspective

Conditions: Terminally Ill

Summary: the goal of this observational study is to explore experiences and perceptions of end-of-life communication in chinese terminally ill patients, families and healthcare providers. the main question it aims to answer is: • what are the experiences and perceptions of end-of-life communication in chinese terminally ill patients, families and healthcare providers? participants will be invited to either semi-structured in-depth interviews or focus group discussions to share their thoughts.

objectives: to explore stakeholders' (patients, families and healthcare providers) experiences and perceptions of end-of-life communication in china; and understand culturally appropriate communication strategies. design and subjects: this study is a qualitative study. eligible patients, family caregivers and healthcare providers will be recruited in two hospitals. purposive sampling methods will be adopted. semi-structured in-depth interviews with patients and family caregivers will be conducted respectively. focus group discussions will be arranged with healthcare providers, allowing them to discuss end-of-life communication and generate group interactions and creative thinking. data analysis: the data analysis will be an iterative, cyclic and self-reflective process. using inductive thematic analysis, common themes and categories will be determined through inductive reasoning and constant comparison. expected results: the study will fill the gap of no empirical evidence on end-of-life communication strategies from a chinese perspective and enrich the knowledge about end-of-life communication.

Eligibility criteria:
inclusion criteria: patients: * be aged older than 18 years * have a defined incurable life-limiting illness with a likely life expectancy of fewer than 12 months (national institute for health and care excellence, 2021), according to the consultation with the patient's physician * have been informed of disease diagnosis and treatment * be able to speak mandarin and express clearly * be able to provide informed consent family caregivers: * be aged older than 18 years * one of the terminally ill patient's primary family caregivers who are familiar with patient's situation, which is defined as lived with or visited patients at least twice a week in the past month * have been informed of patient's disease diagnosis and treatment * be able to speak mandarin * be able to provide informed consent healthcare providers: * be nurses, physicians or other healthcare professionals * be experienced in providing treatment or care to patients with advanced, life-limiting illnesses (whose likely life expectancies of fewer than 12 months) and family caregivers of such patients for at least five years (koh et al., 2016) * consent to participate in the study exclusion criteria: patients and family caregivers: * severe auditory impairment * cognitive impairment

Keywords: communication health personnel terminally ill adult
map-guided preemptive therapy of agvhd

Conditions: GVHD,Acute; Stem Cell Transplant Complications

Summary: acute graft versus host disease (agvhd) is a severe and potentially fatal complication of allogeneic hematopoietic stem cell transplantation (hct). the mount sinai acute gvhd international consortium (magic) algorithm probability (map) identifies patients who are at high risk for severe agvhd as early as 7 days after hct based on 2 serum biomarkers, suppressor of tumorigenesis 2 (st2) and regenerating islet-derived 3α (reg3α). patients who consent to this study will have their blood tested weekly up to four times within the first month post hct to determine if they are at high risk for severe gvhd based on map. patients who are at high risk at any of these four tests will be treated with methylprednisolone to see if it prevents the development of severe agvhd. methylprednisolone starts with the dose of 2 mg/kg for 5 days. if no signs of agvhd, the dose of methylprednisolone is gradually tapered within the following 16 days. patients will be followed for the development of severe agvhd for up to 3 months from the hct and will continue to be followed at routine clinic visits for up to one year after hct.


Eligibility criteria:
inclusion criteria: * any donor type (e.g., related, unrelated, haplo) or stem cell source (bone marrow, peripheral blood, cord blood). * any conditioning regimen (non-myeloablative, myeloablative, or reduced intensity) is acceptable. * gvhd prophylaxis must include a calcineurin inhibitor combined with post transplant cyclophosphamide. * the use of serotherapy to prevent gvhd (e.g., antithymocyte globulin) prior to day 3 post-hct is permitted * direct bilirubin must be \<2 mg/dl unless the elevation is known to be due to gilbert syndrome within 3 days prior to enrollment. * alt/sgpt and ast/sgot must be \<5 x the upper limit of the normal range within 3 days prior to enrollment. * signed and dated written informed consent obtained from patient or legal representative. exclusion criteria: * patients who develop acute gvhd prior to start of study drug * patients at very high risk for relapse post hct as defined by very high disease risk index * patients participating in a clinical trial where prevention of gvhd is the primary endpoint * uncontrolled active infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis) * patients who are pregnant * patients on dialysis within 7 days of enrollment * patients requiring ventilator support or oxygen supplementation exceeding 40% fio2 within 14 days of enrollment. * patients receiving investigational agent within 30 days of enrollment. however, the principal investigator (pi) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of methylprednisolone.
granulocyte transfusion study

Conditions: Blood Transfusion; Infection

Summary: to evaluate granulocyte transfusion therapy with respect to its prophylactic and therapeutic effectiveness to prevent and aid recovery from infection. the study trials were conducted simultaneously.

background: infection remains a major cause of death in patients receiving chemotherapy for malignant diseases. one approach to the problem of septicemia and high mortality in these patients was the therapeutic use of granulocyte transfusions. improvements in collection techniques, employing continuous flow centrifugation, permitted the collection of granulocytes from a single, normal donor in sufficient numbers to study their application in the treatment of infections in granulocytopenic patients. studies had demonstrated the efficacy of granulocyte transfusions as an adjunct in the therapy of septicemia due to gram negative microorganisms associated with granulocytopenia. the aims of the study were to determine (1) whether infections could be prevented in patients who received granulocytes prophylactically and (2) whether recovery from infection was aided in patients who received granulocytes therapeutically. both trials utilized controls who received no granulocytes. four contracts were awarded in september 1976. the protocol designed to evaluate the efficacy of prophylactic granulocyte transfusions was completed at the close of 1977. the protocol for the therapeutic trial was completed in april 1978. approximately 90 patients were randomized in the prophylactic trial and 51 in the therapeutic trial. the recruitment and intervention phase ended in february 1980. the trial has concluded. design narrative: prophylactic trial and therapeutic trial: randomized, non-blind, sequential. eligible patients were randomized to daily granulocyte transfusions or no granulocyte transfusions. the study completion date listed in this record was inferred from the first publication listed in the citations section of this study record.

Eligibility criteria:
prophylactic trial: males and females, 12 years or older, who were in the first induction phase of chemotherapy for acute leukemia, who had severe neutropenia, and who did not have documented infection. therapeutic trial: males and females, any
full pulpotomy in mature teeth with symptomatic irreversible pulpitis as a routine treatment in the primary care clinics

Conditions: Symptomatic Irreversible Pulpitis

Summary: the present study has the objective of being a first approach of the full feasibility study in order to find out whether the full pulpotomy performed by a general practice dentist in a primary care dental clinic at the public health system with limited armamentarium could be suitable and present an appropriate success rate as well as patient satisfaction.

the present study has the objective of being a first approach of the full feasibility study in order to find out whether the full pulpotomy performed by a general practice dentist in a primary care dental clinic at the public health system with limited armamentarium could be suitable and present an appropriate success rate as well as patient satisfaction. this information will help to decide if a multi-center non-randomized intervention designed study is carried out to determine if it is feasible to provide full pulpotomy as a routine treatment to symptomatic irreversible pulpitis or caries pulp exposure at the primary care dental clinics of the public health system in mexico.

Eligibility criteria:
inclusion criteria: all the patients attending the primary care dental clinic with deep caries and/or pain in a permanent premolar or molar tooth. * teeth with complete radicular growth. * preoperative symptoms of irreversible pulpitis (spontaneous pain or exacerbated by thermal stimuli and lasting for a few seconds to several hours interpreted as lingering pain compared with a control tooth and that could be reproduced using thermal testing) exclusion criteria: medically comprised or pregnant patients. * teeth exclusion criteria: * pathological mobility * sinus tract * teeth that cannot be restored with amalgam * radiographic internal or external resorption * presence of apical rarefaction

Keywords: symptomatic irreversible pulpitis full pulpotomy mature teeth
interest of audiovisual distraction in the management of anxiety and pain during oocyte retrieval

Conditions: Fertilization in Vitro

Summary: oocyte retrieval procedure for in vitro fertilization is a source of anxiety for patients. local anaesthesia or sedation are commonly used to manage many situations of anxiety, including the oocyte retrieval. however, this sedation should be as mild as possible in order to preserve oocytes. happymed video glasses are a recent medical device that allows the immersion of patients in films, cartoons or concerts. by distracting patients, this technology can reduce anxiety, discomfort and ultimately pain associated with care. this randomized monocentric trial compares audiovisual distraction versus usual care for the management of anxiety and pain related to oocyte retrieval. hypothesis of this study is that the audiovisual distraction carried out with the happymed video glasses reduces the use of sedative drugs during oocyte retrieval while ensuring a better comfort and a faster walking ability.

consent female patients between 18 and 43 years old scheduled for oocyte retrieval will be enrolled in this study and their anxiety level will be collected via a questionnaire. after randomization, patients will either benefit from audiovisual distraction using happymed video glasses, (medical device with ce marking), or from the usual management during procedure. the anaesthesiologist will check that no anxiolytic or sedative drug was given 12 hours before anaesthesia. the patients will be stratified according to whether or not a previous intervention was performed. anaesthesia will be started and maintained with administration of sufentanil (0.1 μg/kg) and propofol (using the dixon's up-and-down method). the aim is a patient who spontaneously ventilates and does not react to gynaecological stimulation. prevention of postoperative pain and nausea/vomiting will be carried out at the initiation of the surgical procedure. the effect of these drugs is longer than the intervention duration and will not influence the protocol.

Eligibility criteria:
inclusion criteria: * patients undergoing oocyte retrieval requiring a sedation associating sufentanil and propofol * contactable by phone the day after the procedure. * consent for participation * affiliation to the social security system exclusion criteria: * corneal or conjunctival diseases in progress, * claustrophobia * patients under protection of the adults (guardianship, curators or safeguard of justice) * communication difficulties or neuropsychiatric disorder

Keywords: oocyte retrieval sedation